[go: up one dir, main page]

AR015586A1 - PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE. - Google Patents

PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE.

Info

Publication number
AR015586A1
AR015586A1 ARP980101773A ARP980101773A AR015586A1 AR 015586 A1 AR015586 A1 AR 015586A1 AR P980101773 A ARP980101773 A AR P980101773A AR P980101773 A ARP980101773 A AR P980101773A AR 015586 A1 AR015586 A1 AR 015586A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
gastric residence
carbon dioxide
benzamide
allows
Prior art date
Application number
ARP980101773A
Other languages
Spanish (es)
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of AR015586A1 publication Critical patent/AR015586A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Composicion farmacéutica de residencia gástrica que comprende: (a)un principio activo que consiste en una benzamida o una sal de benzamida, (b)un sistemagenerador de dioxido de carbono, y (c)un medio que permite la retencion parcial del dioxido de carbono generado por dicho sistema generador de dioxido decarbono.Pharmaceutical composition of gastric residence comprising: (a) an active substance consisting of a benzamide or a benzamide salt, (b) a carbon dioxide system, and (c) a means that allows the partial retention of carbon dioxide generated by said carbon dioxide generating system.

ARP980101773A 1997-04-18 1998-04-17 PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE. AR015586A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (en) 1997-04-18 1997-04-18 PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION

Publications (1)

Publication Number Publication Date
AR015586A1 true AR015586A1 (en) 2001-05-16

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101773A AR015586A1 (en) 1997-04-18 1998-04-17 PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE.

Country Status (19)

Country Link
EP (1) EP0983065A1 (en)
JP (1) JP2001523241A (en)
KR (1) KR20010006353A (en)
CN (1) CN1252720A (en)
AR (1) AR015586A1 (en)
AU (1) AU737634B2 (en)
CA (1) CA2286081A1 (en)
FR (1) FR2762213B1 (en)
HU (1) HUP0002455A3 (en)
IL (1) IL131995A0 (en)
JO (1) JO2017B1 (en)
MA (1) MA26482A1 (en)
NO (1) NO995039L (en)
NZ (1) NZ500288A (en)
PE (1) PE68199A1 (en)
PL (1) PL336273A1 (en)
TN (1) TNSN98049A1 (en)
WO (1) WO1998047506A1 (en)
ZA (1) ZA983258B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (en) 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
FR2790388B1 (en) * 1999-03-04 2001-04-13 Synthelabo PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
FR2949061B1 (en) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
PT2719376E (en) * 2012-10-12 2015-07-06 Omya Int Ag Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
CN118955352A (en) 2017-12-05 2024-11-15 赛诺维信制药公司 Crystalline forms and methods of preparing the same
CN112118838A (en) 2017-12-05 2020-12-22 赛诺维信制药公司 Non-racemic mixtures and their uses
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (en) * 1978-01-20 1979-08-17 Ile De France NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES
FR2554718B1 (en) * 1983-11-14 1986-04-04 Ethypharm Sa NEW ORAL SULPIRIDE FORMS FOR SULPIRIDE
FR2556964A1 (en) * 1983-12-23 1985-06-28 Ile De France NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY
JPS62178518A (en) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk New long-acting sulpiride tablets
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
WO1998047506A1 (en) 1998-10-29
MA26482A1 (en) 2004-12-20
KR20010006353A (en) 2001-01-26
AU7341698A (en) 1998-11-13
IL131995A0 (en) 2001-03-19
FR2762213A1 (en) 1998-10-23
NZ500288A (en) 2001-03-30
PL336273A1 (en) 2000-06-19
HUP0002455A2 (en) 2000-12-28
HUP0002455A3 (en) 2001-01-29
JP2001523241A (en) 2001-11-20
PE68199A1 (en) 1999-07-15
NO995039D0 (en) 1999-10-15
TNSN98049A1 (en) 2005-03-15
AU737634B2 (en) 2001-08-23
FR2762213B1 (en) 1999-05-14
EP0983065A1 (en) 2000-03-08
NO995039L (en) 1999-12-17
CA2286081A1 (en) 1998-10-29
CN1252720A (en) 2000-05-10
JO2017B1 (en) 1999-05-15
ZA983258B (en) 1998-10-19

Similar Documents

Publication Publication Date Title
CY1107675T1 (en) TRAMADOLIS MEDICINES
CO5580776A2 (en) STABLE PHARMACEUTICAL FORMULATION IN SOLUTION OF OXALIPLATIN
CY1107841T1 (en) PHARMACEUTICAL PARTICULARS CONTAINING MYCOPHENOLIC ACID OR MYCOPHENOLATE SALT
AR015586A1 (en) PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE.
CY1107181T1 (en) Combination of herbicides with acylated aminophenylsulfonylureas
FR2670676B1 (en) HANDLING SYSTEM FOR RESIDUAL MATERIALS, ESPECIALLY MEDICAL.
ES2138584T3 (en) DRUG SUPPLY SYSTEM INVOLVING THE REACTION BETWEEN A PROTEIN OR A POLYPEPTIDE AND A HYDROPHOBIC BIODEGRADABLE POLYMER.
ES2138271T3 (en) 6-DIMETHYL-AMINO-METHYL-1-PHENYL-CYCLHEXAN COMPOUNDS AS A PHARMACEUTICAL ACTIVE PRINCIPLE.
DK0960107T3 (en) 6-Thiosubstituted paclitaxels
ES2143641T3 (en) SURFACE EXPRESSION OF AN ENZYME IN GENE THERAPY BASED ON DRUGS.
CY1105154T1 (en) INCORPORATION OF ACTIVE INGREDIENTS INTO CARRIER MATRICES
DK0703802T3 (en) Intravaginal active substance delivery system
ES2171416T3 (en) REMEDY AGAINST THROMBOCITOPENIA.
ES2052809T3 (en) TUBERCULOCIDE DISINFECTANT AGENT.
ME00578A (en) Use of gastrointestinal lipase inhibitors
ATE438626T1 (en) 4,4-DIFLUORINE-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES AND SALTS THEREOF
ATE260650T1 (en) ORAL DOSAGE FORMS FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
NO171417C (en) METHOD FOR DETECTION AND DETERMINATION OF PEROXYDASE ACTIVITY, A PROCEDURE FOR THE MANUFACTURING OF THE MEDICINE AND ITS USE
IT1314185B1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF SUBSTANCES ACTIVELY SOLUBLE IN AQUEOUS MEDIA
AR034493A1 (en) COMBINATION OF ACTIVE PRINCIPLES FOR THE MEDICAL TREATMENT OF TOXICOMANS.
DE59300631D1 (en) Biodegradable, aqueous dispersions.
ATE240303T1 (en) 1,2,4-TRIAZOLE-3-THIONE COMPOUNDS
ES2080037T3 (en) TOPIC USE MEDICATION WITH CICATRIZING ACTIVITY.
BR9608255A (en) Transdermal therapeutic system (stt) for testosterone administration
ES2084741T3 (en) HERBICIDE COMPOSITION.